<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801852</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-003</org_study_id>
    <nct_id>NCT01801852</nct_id>
  </id_info>
  <brief_title>Autologous Natural Killer T Cells Infusion for the Treatment of Cancer</brief_title>
  <official_title>Phase 1 Study of Autologous Natural Killer T Cells Infusion in Treating Patients With Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tsinghua University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of natural killer T (NKT)&#xD;
      cell-based autologous adoptive immunotherapy in subjects with metastatic,&#xD;
      treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung&#xD;
      cancer, pancreatic cancer, colon cancer or prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled trial on the efficacy and safety of autologous natural killer T (NKT)&#xD;
      cells infusion treatment in advanced cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>Until week 24</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor responses to NKT cells infusions</measure>
    <time_frame>at least once within 30 days afther completing four-cycle treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Glioma</condition>
  <condition>Hepatocellular Cancer</condition>
  <condition>Squamous Cell Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>NKT cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NKT cells treatment plus regular treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NKT cells</intervention_name>
    <arm_group_label>NKT cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:•Male or female not less than 18 years of age or over 80 years of age.&#xD;
&#xD;
          -  Life expectancy of ≥ 24 weeks as measured by the Eastern Cooperative Oncology Group&#xD;
             (ECOG) performance status.&#xD;
&#xD;
          -  Subjects must present with one of the following disease pathologies: Breast Cancer,&#xD;
             Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon&#xD;
             Cancer or Prostate Cancer&#xD;
&#xD;
          -  The pathology must be an assessable disease (measurable by CT scan or MRI) that is&#xD;
             refractory to standard treatments (e.g., chemotherapy, radiation, etc.)&#xD;
&#xD;
          -  Negative for hepatitis B, hepatitis C, HIV, and CMV.&#xD;
&#xD;
          -  Subjects must present with leukocyte counts above 3,000/μL and platelet counts above&#xD;
             100,000/ μL.&#xD;
&#xD;
          -  Subjects must present with minimum hemoglobin levels of 10.&#xD;
&#xD;
          -  If female, subject is surgically sterile (hysterectomy, bilateral tubal ligation, or&#xD;
             bilateral oophorectomy), post menopausal (no menses &gt;12 months), or using a&#xD;
             high-efficiency method of contraception such as implant, injectable, combination oral&#xD;
             contraceptive, intrauterine device (IUD) or sexual abstinence, or has a vasectomized&#xD;
             partner.&#xD;
&#xD;
          -  If female of childbearing potential, subject is not pregnant, breast-feeding or&#xD;
             planning a pregnancy during the study, and has a negative pregnancy test on screening&#xD;
             visit.&#xD;
&#xD;
          -  Able to comprehend and sign an informed consent document and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:•No measurable malignant disease by CT scan or tumor markers.&#xD;
&#xD;
          -  Life expectancy of ≤ 24 weeks as measured by the Eastern Cooperative Oncology Group&#xD;
             (ECOG) performance status.&#xD;
&#xD;
          -  Age of less than 18 years or over 80 years of age.&#xD;
&#xD;
          -  Documented/confirmed positive testing for hepatitis B, hepatitis C, HIV, or CMV.&#xD;
&#xD;
          -  Prior or current history of autoimmune disease.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Leukocyte count &lt; 3,000 /μL prior to leukapheresis.&#xD;
&#xD;
          -  Platelet count &lt; 100,000/μL prior to leukapheresis.&#xD;
&#xD;
          -  Hemoglobin levels below 10.&#xD;
&#xD;
          -  PTT (prothrombin time) of &lt; 12 seconds or &gt; than 15 seconds.&#xD;
&#xD;
          -  aPTT (activated partial thromboplastin time) of &lt; 25 seconds or &gt; than 39 seconds.&#xD;
&#xD;
          -  Failure or refusal to sign informed consent for the study.&#xD;
&#xD;
          -  Culture fails to meet specifications for study.&#xD;
&#xD;
          -  Subject has any other medical condition that, in the opinion of the investigator,&#xD;
             might significantly affect the ability to safely participate in the study or affect&#xD;
             the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Han Weidong, Doctor</last_name>
    <phone>+86-10-66937463</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Minghui, Doctor</last_name>
    <phone>+86-10-13240905431</phone>
    <email>immunolzhang@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Kaichao, Doctor</last_name>
      <phone>+86-10-13811421950</phone>
      <email>timothyfkc@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhang Minghui, Doctor</last_name>
      <phone>86-10-13240905431</phone>
      <email>immunolzhang@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

